GSK and Merck to Study Immunotherapy Combination as Potential Cancer Treatment
Go back to GSK and Merck to Study Immunotherapy Combination as Potential Cancer Treatment| Merck & Co. (NYSE: MRK) | Delayed: 149.28 +0.59 (0.40%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $148.69 | 52 Week High | $65.46 | |||
| Open | $148.17 | 52 Week Low | $47.97 | |||
| Day High | $150.36 | P/E | 101.55 | |||
| Day Low | $146.09 | EPS | $1.47 | |||
| Volume | 7,269,760 | |||||
